Perspectives on the evaluation and adoption of complex in vitro models in drug development : Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate)
Complex in vitro models (CIVM) offer the potential to improve pharmaceutical clinical drug attrition due to safety and/ or efficacy concerns. For this technology to have an impact, the establishment of robust characterization and qualification plans constructed around specific contexts of use (COU) is required. This article covers the output from a workshop between the Food and Drug Administration (FDA) and Innovation and Quality Microphysiological Systems (IQ MPS) Affiliate. The intent of the workshop was to understand how CIVM technologies are currently being applied by pharmaceutical companies during drug development and are being tested at the FDA through various case studies in order to identify hurdles (real or perceived) to the adoption of microphysiological systems (MPS) technologies, and to address evaluation/qualification pathways for these technologies. Output from the workshop includes the alignment on a working definition of MPS, a detailed description of the eleven CIVM case studies presented at the workshop, in-depth analysis, and key take aways from breakout sessions on ADME (absorption, distribution, metabolism, and excretion), pharmacology, and safety that covered topics such as qualification and performance criteria, species differences and concordance, and how industry can overcome barriers to regulatory submission of CIVM data. In conclusion, IQ MPS Affiliate and FDA scientists were able to build a general consensus on the need for animal CIVMs for preclinical species to better determine species concordance. Furthermore, there was acceptance that CIVM technologies for use in ADME, pharmacology and safety assessment will require qualification, which will vary depending on the specific COU.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
ALTEX - 39(2022), 2 vom: 22., Seite 297–314 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baran, Szczepan W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Context of use |
|---|
| Anmerkungen: |
Date Completed 14.04.2022 Date Revised 16.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.14573/altex.2112203 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335988547 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335988547 | ||
| 003 | DE-627 | ||
| 005 | 20231225231118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14573/altex.2112203 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335988547 | ||
| 035 | |a (NLM)35064273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baran, Szczepan W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perspectives on the evaluation and adoption of complex in vitro models in drug development |b Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2022 | ||
| 500 | |a Date Revised 16.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Complex in vitro models (CIVM) offer the potential to improve pharmaceutical clinical drug attrition due to safety and/ or efficacy concerns. For this technology to have an impact, the establishment of robust characterization and qualification plans constructed around specific contexts of use (COU) is required. This article covers the output from a workshop between the Food and Drug Administration (FDA) and Innovation and Quality Microphysiological Systems (IQ MPS) Affiliate. The intent of the workshop was to understand how CIVM technologies are currently being applied by pharmaceutical companies during drug development and are being tested at the FDA through various case studies in order to identify hurdles (real or perceived) to the adoption of microphysiological systems (MPS) technologies, and to address evaluation/qualification pathways for these technologies. Output from the workshop includes the alignment on a working definition of MPS, a detailed description of the eleven CIVM case studies presented at the workshop, in-depth analysis, and key take aways from breakout sessions on ADME (absorption, distribution, metabolism, and excretion), pharmacology, and safety that covered topics such as qualification and performance criteria, species differences and concordance, and how industry can overcome barriers to regulatory submission of CIVM data. In conclusion, IQ MPS Affiliate and FDA scientists were able to build a general consensus on the need for animal CIVMs for preclinical species to better determine species concordance. Furthermore, there was acceptance that CIVM technologies for use in ADME, pharmacology and safety assessment will require qualification, which will vary depending on the specific COU | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a context of use | |
| 650 | 4 | |a microphysiological systems | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Brown, Paul C |e verfasserin |4 aut | |
| 700 | 1 | |a Baudy, Andreas R |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzpatrick, Suzanne C |e verfasserin |4 aut | |
| 700 | 1 | |a Frantz, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Fullerton, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Jinping |e verfasserin |4 aut | |
| 700 | 1 | |a Hardwick, Rhiannon N |e verfasserin |4 aut | |
| 700 | 1 | |a Hillgren, Kathleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Kopec, Anna K |e verfasserin |4 aut | |
| 700 | 1 | |a Liras, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Mendrick, Donna L |e verfasserin |4 aut | |
| 700 | 1 | |a Nagao, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Proctor, William R |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsden, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, Alexandre J S |e verfasserin |4 aut | |
| 700 | 1 | |a Stresser, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sung, Kyung E |e verfasserin |4 aut | |
| 700 | 1 | |a Sura, Radhakrishna |e verfasserin |4 aut | |
| 700 | 1 | |a Tetsuka, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tomlinson, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Van Vleet, Terry |e verfasserin |4 aut | |
| 700 | 1 | |a Wagoner, Matthew P |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Arslan, Sevim Yildiz |e verfasserin |4 aut | |
| 700 | 1 | |a Yoder, Gorm |e verfasserin |4 aut | |
| 700 | 1 | |a Ekert, Jason E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ALTEX |d 1988 |g 39(2022), 2 vom: 22., Seite 297–314 |w (DE-627)NLM110013646 |x 1868-8551 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:2 |g day:22 |g pages:297–314 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14573/altex.2112203 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 2 |b 22 |h 297–314 | ||